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Background: Osteogenesis imperfecta (OI) also known as brittle bone disease, is 
a genetic pathology in which bones do not form properly and therefore are fragile 
and break easily. Is a heterogeneous congenital heritable disease that mainly 
affects connective tissues. Nowadays we number 18 types of OI, distinguished 
into autosomal dominant, recessive and X-linked inheritance. OI type VI is 
caused by loss-of-function mutations in SERPINF1, which shows recessive 
inheritance. Lack of the gene product, PEDF, causes an atypical bone 
mineralization defect determining a unique clinical phenotype.  
Aim: the aim of the study is to identify genomic, epigenomic and metabolomic 
variations that are associated to the disease status in individuals that belong to a 
nuclear Pakistan family in which is supposed to be segregate type VI osteogenesis 
imperfecta. 
Results: exome sequencing confirmed the consanguinity between the parents and 
shared regions of homozygosity between affected were observed in chr7, chr12 
and chr22.  In the hypothesis of Autosomal Recessive disease, any compatible 
mutation was found, and no clear pathogenic variant have been detected. Thus, we 
explore compound heterozygosis model, identifying and suggesting as potential 
candidate CERCAM gene, but it is role in bone homeostasis it is still unknown. 
Epigenetic investigation highlights some interesting genes, known to be involved 
in bone metabolism, such as RXRA (Retinoid X Receptor Alpha), ELK3 (ETS 
Transcription Factor) and GLI2 (GLI Family Zinc Finger 2).  
Metabolomic profiling found 4 modulated pathways: phenylalanine, tyrosine and 
tryptophan biosynthesis, tryptophan metabolism, pyrimidine metabolism, and 
Vitamin B6 metabolism.  
Conclusions: the future investigation will try to enhance and integrate the results 
from the present omics (transcriptomic analysis is ongoing) into a context of 
system biology aimed to depict and clarify the defects and biological processes 





1.1 Bone cells and tissue  
Bone is a rigid organ that provides support and physical protection to various vital 
organs of the body. Throughout life, bone is in dynamic balance involving a 
complex coordination of multiple bone marrow cell types. It contains a relatively 
small number of cells entrenched in a matrix of collagen fibers that provide a 
surface for inorganic salt crystals to adhere. Although bone cells account for a 
small amount of the bone volume, they are crucial for bone functions. Four types 
of cells are found within bone tissue: osteoblasts, osteocytes, osteoclasts and 
mesenchymal stem cells. Osteoblasts are responsible for forming new bone and 
are found in the growing portions, including the periosteum and endosteum. 
Osteoblasts, which do not divide, synthesize and secrete the collagen (mainly type 
I) matrix and calcium salts. As the secreted matrix surrounding it calcifies, the 
osteoblast becomes trapped within it; as a result, it changes in structure and 
becomes an osteocyte, the primary cell of mature bone and the most common 
type of bone cell. Each osteocyte is located in a space called a lacuna and is 
surrounded by bone tissue. Osteocytes maintain the mineral concentration of the 
matrix via the secretion of enzymes. Like osteoblasts, osteocytes lack mitotic 
activity. They can communicate with each other and receive nutrients via long 
cytoplasmic processes that extend through canaliculi, channels within the bone 
matrix. The dynamic nature of bone means that new tissue is constantly formed, 
and old, injured, or unnecessary bone is dissolved for repair or for calcium release. 
The cell responsible for bone resorption, or breakdown, is the osteoclast. 
Osteoclasts are found on bone surfaces, they are multinucleated, and originate 
from monocytes and macrophages, two types of white blood cells, not from 
osteogenic cells. Osteoclasts are continually breaking down old bone while 
osteoblasts are continually forming new bone. The ongoing balance between 
osteoblasts and osteoclasts is responsible for the constant but subtle reshaping of 
bone.  
If osteoblasts and osteocytes are incapable of mitosis, then how are they replaced 
when old ones die? The answer is a fourth category of cells: the mesenchymal 
stem cells. These cells are undifferentiated with high mitotic activity and they are 
the only bone forming cells able to divide. 
 
1.2 Mesenchymal stem cells - osteoblast differentiation   
Mesenchymal stem cells (MSCs), a non-hematopoietic stem cell population first 
discovered in bone marrow, are multipotent cells capable of differentiating into 
mature cells of several mesenchymal tissues, such as cartilage, bone, tendon, 
ligament, and adipose tissue. As common progenitor cells of adipocytes and 
osteoblasts, MSCs are delicately balanced for their differentiation commitment.1 
The differentiation of MSCs is a two-step process: lineage commitment (from 
MSCs to lineage-specific progenitors) and maturation (from progenitors to 
specific cell types). Recently it has been demonstrated that lineage commitment of 
MSCs involves the regulation of a large number of critical signalling pathways, 
including transforming growth factor-beta (TGFβ)/bone morphogenic protein 
(BMP) signalling, wingless-type MMTV integration site (Wnt) signalling, 
Hedgehogs (Hh), Notch, and fibroblast growth factors (FGFs). Wnt signalling is 
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involved in many critical biological processes, including 
development,2metabolism,3 and stem cells maintenance.4Binding to the 7-
transmembrane domain spanning Frizzled receptor (FZD) and LRP5/6 
coreceptors, Wnt ligands stabilize β-catenin via preventing its phosphorylation 
and degradation. 5 The activation of Wnt signalling has been reported to promote 
osteogenic differentiation and inhibit adipogenic differentiation of MSCs.6 Wnt3a 
has been specifically shown to stimulate osteogenic differentiation through 
activation of TAZ by PP1A-mediated dephosphorylation.7 Most recently, it has 
been demonstrated that YAP/TAZ could mediate alternative Wnt signalling-
induced osteogenesis.8 Animal studies showed that activation of Wnt signalling by 
overexpression of Wnt10b or lithium supplementation could increase the 
thickness of trabecular bone.9 Accordingly, deficiency of Wnt10b leads to a 
decrease in bone density. Aging-related increase in adipocytes is also thought to 
be related to the reduction of Wnt10b.10,11 In addition, the loss of β-catenin in the 
mesenchyme of the developing mouse uterus was found to cause a switch to 
adipogenesis in the myometrium.12 These studies provide strong evidence for the 
role of Wnt signalling in regulating the balance between adipogenic and 
osteogenic differentiation of MSCs. Committed MSCs are also known as 
osteogenic cells, they are found in the deep layers of the periosteum and the 
marrow. They differentiate and develop into osteoblasts. Runx2 and Osterix are 
considered as master transcription factors regulating osteogenic differentiation of 
MSCs. 13 During osteoblast differentiation, most signalling pathways investigated 
so far target Runx2, which in turn induces Osterix expression.14 Upregulation of 
Runx2 in MSCs promotes their differentiation potential into immature 
osteoblasts, while inhibits their lineage commitment to adipocytes.15 In addition, 
Runx2 has been shown to be required for the induction of major bone matrix 
genes in immature osteoblasts, while it is unnecessary for the maintenance of 
these genes in mature osteoblasts.  
1.3 Bone development  
Bone is a dynamic organ, able to replace old or disrupted tissue through a 
remodelling process.16, Skeleton undergoes a lifelong continuous turnover 
depending on age, sex, ethnical group and on individual health condition. It has 
been estimated that the entire skeleton is remodelled every 10 years.17 
Bone is a replacement tissue, that is, it uses a model tissue on which to lay down 
its mineral matrix. For skeletal development, the most common template is 
cartilage. During foetal development, a framework is laid down that determines 
where bones will form. This framework is a flexible, semi-solid matrix produced 
by chondroblasts and consists of hyaluronic acid, chondroitin sulphate, collagen 
(mainly type II) fibers, and water. Throughout foetal development and into 
childhood growth and development, bone forms on the cartilaginous matrix. By 
the time a foetus is born, most of the cartilage has been replaced with bone. Some 
additional cartilage will be replaced throughout childhood, and some cartilage 
remains in the adult skeleton. By the sixth or seventh week of embryonic life, the 
actual process of bone development, ossification (osteogenesis), begins.  
 
1.4 Bone ossification in the foetus  
Two osteogenic process characterize skeletal development: intramembranous and 
endochondral ossifications. Ossification is a complex process orchestrated by 
Mesenchymal Stem Cells (MSCs) able to differentiate either into osteoblasts or 
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chondrocytes. In intramembranous ossification MSCs direct differentiate into 
osteoblasts and usually occurs in the flat bones as skull, jaw and in the sub-
periosteum areas of long bones. Early osteoblasts occur in cluster called 
ossification centre, although osteoblasts will be spreaded out by during formation 
of bone. Osteoblasts secrete osteoid, an uncalcified matrix, which within a few 
days calcifies trough a mineral salts deposition, thereby entrapping the osteoblasts 
in the matrix. Entrapped osteoblasts will become osteocytes. As osteoblasts-
osteocytes transformation, also osteogenic cells present in the surrounding 
connective tissue may differentiate into new osteoblasts. Unmineralized bone 
matrix secreted around the capillaries became a trabecular matrix, while 
osteoblasts on the surface of the spongy bone form the periosteum. The 
periosteum represents the protective surface layer above trabecular bone. 
Intramembranous ossification that begins during foetal development prosecute 
until adolescence. At birth, the skull and clavicles bones are not fully ossified. 
Bones plasticity allow skull and shoulders to deform during passage through the 
birth canal. In endochondral ossification, process that occurs in long bones 
formation, mesenchymal stem cells differentiate into chondrocytes and secrete a 
cartilaginous matrix. Cartilage scaffolds are then replaced by bone, increasing the 
ability to counteract the compression.19 For example, six-eight weeks after 
conception, mesenchymal cells differentiate into chondrocytes which form the 
cartilaginous skeletal precursor of a long bone. The canonical bone development 
model involves the differentiation of mesenchymal stem cells into a specific cell 
lineage fate, depending on the time and signalling. As more matrix is produced, 
more chondrocytes grow in size. Matrix calcification, inhibits nutrients reaching to 
the chondrocytes. During cartilage grows, capillaries penetrate it, starting the 
transformation of perichondrium into the bone-producing periosteum. Here, 
osteoblasts form a periosteal compact bone frame that surround the diaphysis 
cartilage. From the third month of foetal life, in the periosteal collar bone 
development create the primary ossification centre, where ossification begins. 
Chondrocytes and cartilage continue to grow at the ends of the bone, forming the 
future epiphyses. While length increases, bone is replacing cartilage in the 
diaphysis. When the foetal skeleton is fully formed, cartilage remains only at the 
joint surface and between the diaphysis and epiphysis. After birth, matrix 
mineralization, chondrocytes’ death, invasion of blood vessels from the 
periosteum, and osteoblasts maturation occurs in the epiphyseal regions, and all 
these activities centres is referred to as a secondary ossification centre.  
 
1.5 Childhood and adolescence 
Childhood and adolescence are characterized by a progressive growing (fig. 1) of 
bone dimensions and by the enhanced bone mass. At birth the weight of the 
skeleton is around 75-90 g; it reaches 2400-3000 g in the young-adult.19 The 
epiphyseal plate is the area of growth in a long bone. It is a layer of hyaline 
cartilage where ossification occurs in immature bones. The reserve zone is the 
region closest to the epiphyseal end of the plate and contains small chondrocytes 
within the matrix, these cells do not participate in bone growth but secure the 
epiphyseal plate to the osseous tissue of the epiphysis. The proliferative zone is 
the next layer toward the diaphysis and contains stacks of slightly larger 
chondrocytes. It makes new chondrocytes (via mitosis) to replace those that die at 
the diaphyseal end of the plate. Chondrocytes in the next layer, the zone of 
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maturation and hypertrophy, are older and 
larger than those in the proliferative zone. 
The more mature cells are situated closer 
to the diaphyseal end of the plate. The 
longitudinal growth of bone is a result of 
cellular division in the proliferative zone 
and the maturation of cells in the zone of 
maturation and hypertrophy. Most 
chondrocytes in calcified matrix, the zone 
closest to the diaphysis, are dead because 
the matrix around them has calcified. 
Capillaries and osteoblasts from the 
diaphysis penetrate this zone; osteoblasts 
secrete bone tissue on the remaining 
calcified cartilage. Thus, the zone of 
calcified matrix connects the epiphyseal 
plate to the diaphysis. A bone grows in 
length when osseous tissue is added to the 
diaphysis. The growth rate is controlled by 
hormones, bones continue to grow in 
length until early adulthood. Bone growth 
includes also increasing in diameter, this can continue even after longitudinal 
growth ceases and it is called appositional growth. Osteoclasts resorb old bone 
that lines the medullary cavity, while osteoblasts, via intramembranous 
ossification, produce new bone tissue beneath the periosteum. 
 
1.6 Bone remodelling 
The process in which matrix is resorbed on one surface of a bone and deposited 
on another is known as bone modelling. Modelling primarily acts during a bone’s 
growth. However, also during adult life, bone undergoes to remodelling, in which 
resorption of old or damaged bone takes place on the same surface where osteo-
blasts lay new bone to replace that which is resorbed. Injury, exercise, and other 
activities lead to remodelling. Normally about 5 to 10 percent of the skeleton is 
remodelled annually just by destroying old bone and renewing it with fresh bone. 
The remodelling process takes place under the control of various players, i.e., par-
athyroid hormone (PTH), calcitonin, vitamin D, growth hormone (GH), steroids, 
soluble cytokines and growth factors (i.e., Macrophage Colony-Stimulating Factor 
(M-CSF), Receptor Activator of Nuclear κB Ligand (RANKL), Vascular Endothe-
lial Growth Factor (VEGF), Interleukin-6 (IL-6) family.20 Different stimuli, such 
as microenvironmental factors, induce osteoblasts to produce RANKL which in-
teracts with its receptor RANK (Receptor Activator of Nuclear _B), expressed by 
osteoclasts. This interaction determines osteoclast polarization and secretion of 
the enzymes required for bone resorption. Osteoblasts, which interact with bone 
matrix through integrins, synthesize type I collagen (that represents 90% of the 
proteins in the bone matrix). Unmineralized osteoid is composed of type I colla-
gen together with other fibrillar collagens, bone proteins (osteopontin, bone si-
aloprotein and osteocalcin), proteoglycans, fibronectin, etc. PEDF (pigment epi-
thelium derived factor) is necessary for osteoblast development; it stimulates the 
expression of osteogenic genes and mineral deposition21 and it also stimulates the 
Figure 1: longitudinal Bone Growth 
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production of osteoprotegerin, thus inhibiting osteoclast maturation. Mineraliza-
tion then occurs thanks to the activity of osteoblast phosphatases, releasing phos-
phates that together with calcium form hydroxyapatite crystals.22  
 
1.7 Osteogenesis imperfecta: history and phenotype 
Perturbation or disruption of the molecular pathways controlling MSC 
proliferation and osteogenic commitment may be due to mutations in key genes in 
bone development. Osteogenesis Imperfecta (OI) also known as brittle bone 
disease, is a genetic pathology in which bones do not form properly and therefore 
are fragile and break easily23. 
Is a heterogeneous congenital heritable disease that mainly affects connective 
tissues. The estimated incidence is approximately 1 per 20,000 live births.24 The 
various genetic mutations that cause OI in 85% of cases affect type I collagen- 
one of the critical components of bone matrix, either quantitatively or 
qualitatively,25 The first studies on OI were done in 1788 by Olof Jakob Ekman; it 
can actually be considered a very ancient pathology. During archaeological studies 
some Egyptian mummies were found; the description of their skull, teeth and flat 
bones abnormalities suggests that they affected by OI. In 1979 Sillence et al 
described OI as a heterogeneous disease and, for the first time, they proposed a 
classification of at least four distinct types.24 The hallmarks of the brittle bone 
dysplasia osteogenesis imperfecta are skeletal deformities and bone fragility that 
causes low bone mass and bone fractures.87 The severity of the disease can range 
from mild to lethally severe. Frequent and multiple fractures typically lead to bone 
deformities and short stature. Since type I collagen is such an important structural 
protein in many parts of the body, people with OI may also experience fragile 
skin, weak muscles, loose joints, easy bruising, frequent nosebleeds, brittle teeth, 
blue sclerae, and hearing loss. The clinical features can be classified into skeletal 
and extra skeletal. Skeletal features include excess or atypical fractures, short 
stature, scoliosis, and basilar skull deformities. Extra skeletal manifestations 
include hearing loss which is a mixture of conductive and hearing loss and seen in 
50% of adults by 50 years and in 5% of children with OI.26 Dentinogenesis 
Imperfecta (DI), consist in small deformed teeth, which present opalescent and 
opaque dentin. Malocclusion and DI, are the main dental abnormalities which 
may occur. The phenotype is variable also within the same patient, with some 
teeth appearing normal and others being affected. The sclerae may be blue or 
gray.27 Connective tissue abnormalities may result in dislocation of head of the 
radius and the joint. 36% of patients that manifest hypercalciuria, may result in 
renal calculi. Cardiovascular involvement leads to aortic root dilatation and mitral 
valve prolapse. Neurological manifestations include macrocephaly, hydrocephalus, 
basilar invagination and cervical spine kyphosis.27 
 
1.8 Genetic classification and pathophysiology of OI 
Mutations in genes coding for the α1 and α2 chains of type I collagen (COL1A1 
and COL1A2) were associated to Osteogenesis imperfecta disease in 1980. 
Mutations in these genes are the most common cause and are transmitted as 
autosomal dominant traits.  They cause a quantitative loss of α1(I) chain and, with 
few exceptions, they cause a mild form of OI (type I) because the other allele 
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produces collagen of normal quality and structure.28 Other mutations in either 
COL1A1 or COL1A2, most often glycine substitutions in the Gly-X-Y repeat, 
cause structural defects of the collagen triple helix. They exert a dominant 
negative effect on the normal collagen chains upon trimers formation, and result 
in moderate, severe or lethal OI. Type I collagen is the most abundant protein of 
bone, skin, and tendon extracellular matrices; in bone and theeth it plays a 















In the past decade, a wide variety of genes encoding proteins involved in type I 
collagen synthesis, processing, secretion and post-translational modification, as 
well as in genes coding for proteins that regulate the differentiation and activity of 
bone-forming cells have been shown to cause osteogenesis imperfecta.29 In 2006 
The first gene causing recessive osteogenesis imperfect was identified, opening the 
way to a burst of exciting new information about the genetics and mechanism of 
this bone dysplasia. 
The OI classification initially included four phenotypes (I-IV) involving COL1A1 
and COL1A2 mutations.30 The large number of causative genes discovered since 
2006 has complicated the classic classification of the disease, and, although a new 
genetic classification system is widely used, it is still debated. Defects in proteins 
with very different functions, ranging from structural to enzymatic and from 
intracellular transport to chaperones, have been described in patients with 
osteogenesis imperfecta. Nowadays we number 18 types of OI, distinguished into 
autosomal dominant, recessive and X-linked inheritance. An appropriate 
Figure 2: type I collagen synthesis and processing. A) translation and post-translational 
modifications of pro α1 and pro α2. B) Interaction with molecular chaperones to prevent premature 
triple helix formation. C) triple helix formation that comprises two pro α1 chains and one pro α2 
chain. D) secretion of protocolagen, extracellular cleavage to collagen and crosslinking. 
ADAMTS2, a disintegrin and metalloproteinase with trombospondin motifs 2; BMP1, bone 
morphogenetic protein1; CTRAP, cartilage-associated protein; GLT, galactosyltransferase 1 ; 
InsP3R, inositol-1,4,5-triphosphate receptor; LH, lysyl hydroxylase; P3H1, propyl 3-hydroxylase 1; 
P4H1, propyl 4-hydroxylase 1; PPIase B, peptidyl-prolyl cis-trans isomerase B; rER, rough 
endoplasmic reticulum; TANGO1, transport and Golgi organization protein 1; TRIC-B, trimeric 
intracellular cation channel type B (figure from Marini e al)29.  
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pathophysiology-based grouping of types, as proposed by JC Marini et al., appears 





1.9 Defects in bone mineralization  
Bone mineralization defects have been associated with mutations in two genes: 
IFITM5, which encodes for BRIL (Bone Restricted Ifitm-Like protein) and 
SERPINF1, which encodes for PEDF (pigment epithelium-derived factor) The 
causative mutations are directly responsible for OI type V and VI, respectively, 
(fig. 3 Defects in bone formation and mineralization in osteogenesis imperfecta).29 
All cases of type V OI are caused by a dominantly inherited or “de novo” 
recurrent heterozygous mutation (c.-14C>T) in the 5’-UTR of IFITM5, a 
transmembrane protein enriched in osteoblasts during mineralization.31 Patients 
with type V OI have a moderately severe bone dysplasia and fracture incidence, 
including vertebral compressions and, often, scoliosis. Features of type V include 
radial head dislocation, ossification of the forearm interosseous membrane, and 
hyperplastic callus. There is also a radiographically dense band prominent in the 
forearm metaphyses. 32,33 
Loss-of-function mutations in SERPINF1 are responsible for OI type VI, which 
shows recessive inheritance. Lack of the gene product, PEDF, causes an atypical 
bone mineralization defect determining a unique clinical phenotype.34 Patients 
with type VI OI show bone dysplasia, with clinical characteristics and bone 
histology distinct from type V OI. Types V and VI osteogenesis imperfecta, 
although genetically different, share the distinctive feature of causing primary 
defects in endochondral bone ossification and/or mineralisation.  
 
Mutaded gene Encoded protein Inheritance Localization Severity OI type
COL1A1 Col lagen α1 AD matrix s tructura l  component Mi ld to letha l  I ,II ,I II  or IV
COL1A2 Col lagen α2 AD matrix s tructura l  component Moderate to lethal  I ,I I ,I I I  or IV
IFITM5 BRIL AD
bone-restriced interferon-induced 
transmembrane l i ke protien variable s everi ty V
SERPINF1 PEDF AR
col lagen-binding protein/pigment 
epi thel ium derived factor Moderate to s evere VI
CTRP CTRAP AR endoplas mic reticul um Severe to lethal  VII
P3H1 (LEPRE1) P3H1 AR endoplas mic reticul um Severe to lethal  VII I
PPIB PPIase B AR endoplas mic reticul um Moderate to s evere IX
SERPINH1 HSP47 AR endoplas mic reticul um-golgi Severe to lethal  X
FKBP10 FKBP65 AR endoplas mic reticul um Moderate to s evere XI
PLOD2 LH2 AR endoplas mic reticul um Moderate to s evere no type
BMP1 BMP1 AR endoplas mic reticul um Moderate to s evere XII
SP7
Transcription 
factor SP7/ AR nucleus Mi ld to moderate XII I
TMEM38B TRIC-B AR cation channel  Moderate to s evere XIV
WNT1 WNT1 AR/AD secreted s ignal  molecule Moderate to s evere XV
CREB3L1 OASIS AR endoplas mic reticul um-golgi Severe XVI
SPARC SPARC/osteonectinAR matrix Moderate to s evere XVII
MBTPS2 S2P XLR endoplas mic reticul um-golgi Moderate to s evere XVII I
Impairment of collagen suntheis and structure
Compromised bone mineralization
Abnormal collagen post-translational modification
Compromised collagen processing and crosslinking 
Alterate osteoblast differentiation and function




Figure 3: defects in bone formation and mineralization in osteogenesis imperfecta. a | 
Bone remodelling. Bone formation consists of the secretion of bone extracellular matrix 
components (mainly type I collagen) by osteoblasts. The unmineralized bone matrix 
(osteoid) subsequently becomes mineralized. In addition, osteoblasts and osteocytes 
release many cytokines, including receptor activator of nuclear factor-κB ligand (RANKL; 
also known as TNFSF11) and osteoprotegerin (OPG), which regulate bone resorption by 
osteoclasts. RANKL acts on osteoclast precursor cells by binding to receptor activator of 
nuclear factor-κB (RANK; also known as TNFRSF11A) on their surface, thereby favouring 
their differentiation to osteoclasts. OPG, by interacting with RANKL, prevents the binding 
of RANKL to RANK. Some osteoblasts become embedded in the mineralized bone matrix 
and differentiate to osteocytes, which produce, among other factors, sclerostin, an 
inhibitor of the WNT pathway that is known to stimulate bone formation by stimulating 
osteoblast activity. b | WNT1 is a secreted ligand that stimulates the transcription of 
genes involved in osteoblast differentiation by interacting with the receptors low-density 
lipoprotein receptor-related protein 5/6 (LRP5/6) and Frizzled on osteoblast precursor 
cells. Endopeptidase S2P is a protease in the Golgi membrane that is involved in regulated 
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intramembrane proteolysis (RIP) of transcription factors, such as old astrocyte specifically 
induced substance (OASIS), which is transported from the endoplasmic reticulum (ER) 
membrane for processing in times of ER stress. Pigment epithelium-derived factor 
(PEDF) is a multifunctional secreted protein with anti-angiogenic activity; bone-restricted 
interferon-induced transmembrane protein-like protein (BRIL) is a transmembrane 
protein involved in mineralization. Crosstalk between the two proteins had been 
elucidated following mutations identified in patients with osteogenesis imperfecta. 
Dashed lines indicate unknown pathways. InsP3R, inositol-1,4,5-triphosphate receptor; 
OASIS-N, N-terminal part of OASIS; MALEP, methionine, alanine, leucine, glutamate 
and proline pentapeptide; S40L, p.Ser40Leu substitution; TRIC-B, trimeric intracellular 
cation channel type B; VEGF, vascular endothelial growth factor (figure from Marini e 
al)29. 
1.10 Phenotypical aspects OI type VI 
Bone histology is remarkable for broad bands of unmineralized osteoid and a fish-
scale pattern under polarized light.25 Patients affected by OI type VI do not have 
fractures at birth, but starting from ≥6 mo. age, they suffer from frequent 
fractures, progressive bone deformity, vertebral compressions and scoliosis. 
Growth deficiency in type VI is moderately severe, sclerae are white and teeth are 
normal.35 A variety of recessive null mutations in SERPINF1 has been reported. 
36,37,38,39 Serum PEDF is virtually absent in type VI OI patients, while normal 
PEDF values are reported in type V OI, as well as in OI caused by collagen 
defects (types I, III, and IV).39 Children with type VI OI have elevated serum 
alkaline phosphatase levels; with a mean of 409 U/L (range 200-650 U/L).29 
Other biochemical parameters of bone and mineral metabolism are within the 
reference range.35 
 
1.11 Molecular and cellular features of OI type VI  
PEDF is a ubiquitously expressed secreted protein best known as a potent anti-
angiogenic factor that inhibits tumour growth and metastasis. 40,31 This protein is 
able to bind two distinct sites on type I collagen41, and this binding is critical to its 
anti-angiogenic function.42,43 One binding site overlaps the heparin and heparan 
sulphate proteoglycan binding site with the α1(I) C-terminal major ligand binding 
region. The second collagen-binding site, in the α1(I) N-terminal, overlaps 
integrin collagen-binding sites. The variety of recessive null mutations 
in SERPINF1 determine the absence of PEDF in the serum.44 In bone, PEDF 
acts at many levels to maintain bone homoeostasis and regulate osteoid 
mineralisation. PEDF positively affects osteoblast development by favouring the 
expression of osteogenic genes and mineral deposition. It inhibits osteoclast 
maturation by stimulating osteoprotegerin expression.45 The absence of PEDF 
increases osteoclast number and bone resorption by favouring RANKL binding 
to the osteoclast RANK receptor. Moreover, it impairs the proper transition of 
osteoblast to osteocyte, consequently causing a defective mineralization that leads 
to brittle bone.46 Importantly, an intact collagen-binding site on PEDF is required 
for its anti-angiogenic activity. PEDF, appears also to be involved in a poorly 
characterized signalling pathway that includes the plasma membrane 
receptor BRIL, encoded by IFITM5.34 
 
1.12 Multi-omics analysis  
The advent of genotyping arrays and next generation sequencing (NGS) platform 
enabled large-scale genome-wide studies opening the arrival of genomics, 
transcriptomics and metabolomics. 
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Osteogenesis imperfecta had been known since the early 1980s as a disease caused 
by mutations in either of the genes encoding type I collagen (COL1A1 and 
COL1A2). Since 2006 the NGS revolution applied to OI, combined with the 
traditional approaches, has unravelled new mutations in collagen-related genes 
with different inheritance patterns.47 Fifteen novel disease OI associated loci have 
been discovered in ten years’ time.48 
The appearance of “omics” to a molecular term implies a comprehensive, or 
global, assessment of a set of molecules.53 
Genomics is an interdisciplinary field of science focusing on the structure, 
function, evolution, mapping, and editing of genomes. A genome is a complete 
set of DNA, including all genes of an individual. In contrast to genetics, which 
refers to the study of individual genes and their roles in inheritance, genomics 
aims at the collective characterization and quantification of genes. Likewise, 
transcriptomics refers to all RNA molecules in one cell or a population of cells. 
Despite the DNA, that remains unchanged in every cell of one individual, RNA 
molecules reflect the expression profile a set of transcripts in of a specific cell 
type. Proteomics is used to quantify peptide abundance, modification, and 
interaction. Metabolomics simultaneously quantifies multiple small molecule 
types, such as amino acids, fatty acids, carbohydrates, or other products of cellular 
metabolic functions. Metabolite levels and relative ratios reflect metabolic 
function, and out of normal range perturbations are often indicative of disease. 
Quantitative measures of metabolite levels have made possible the discovery of 
novel genetic loci regulating small molecules, or their relative ratios, in plasma and 
other tissues.49,50Additionally, metabolomics in combination with modelling has 
been used extensively to study metabolite flux. Associated technologies include 
Mass Spectrometry (MS)-based approaches to quantify both relative and targeted 
small molecule abundances. 51,52 
The omics field has been driven largely by technological advances that have made 
cost-efficient, high-throughput analysis of biologic molecules possible.53 Taken 
together, these understanding provides a rationale for the development of system 
biology technologies that involve the integration of different omics data to 
identify molecular patterns associated with disease.53  The advantage of multi-
omics approach is to offers the opportunity to understand the flow of 
information that underlies disease.   
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2. AIMS OF THE STUDY 
The aim of the study is to investigate the possible defects that might be detected 
at genomic, epigenomic and metabolomic level, related to the disease status in 
individuals that belong to a nuclear Pakistan family in which is supposed to 
segregate a form of type VI osteogenesis imperfecta (see fig. 4).  
We performed a multi-omics approach in order to:  
 Discover possible genetic defects by exome sequencing  
 Assess epigenetic modifications associated with the disease status of 
individuals, in particular we investigated DNA methylation using Next 
Generation Sequencing technology (NGS)  
 Detect the metabolic pathways associated with the disease performing an 




















Figure 4: pedigree of the family that has been investigated at genetic, 






















3. MATERIALS AND METHODS 
3.1 Subjects 
The family settled in Italy in 2009, it is composed by 2 parents (individuals I-1, I-
2) and 5 children, 3 males (individuals II-1, II-3, II-5) and 2 females (individuals 
II-2, II-4) (in fig.4 pedigree of the family). Since 2010 the family, and in particular 
the affected sisters (individuals II-2, II-4), have been monitored and supervised by 
an interdisciplinary team of Italian paediatricians and bone experts at Verona 
University Hospital (AOUI). The two daughters present all phenotypical traits 
characteristic of Osteogenesis Imperfecta type VI. At birth both babies (individual 
II-2 and II-4) were fractureless, but at the age of 6 months they manifested the 
first fractures and bone mineralization defects.  
In the absence of any causative mutation in known candidate genes that could 
explain that pathology we decided to proceed with a multi-omics approach. 
 
3.2 Bone biopsies - hystomorfometric analysis 
Iliac crest bone biopsy was collected from the affected children. The samples were 
fixed in 70% and 100% ethanol and embedded undecalcified in methyl-
methacrylate resin (Merck 800590). Bone sections were cut by using a microtome 
(Polycut S, Leica Microsystems) equipped with a carbide-tungsten blade, stained 
with Goldner’s stain and mounted on microscope slides for histomorphometric 
measurements. Measurements were performed by means of an image analysis 
system consisting of an epifluorescent microscope (Leica DM2500) connected to 
a digital camera (Leica DFC420 C) and a computer equipped with a specific 
software for histomorphometric analyses (Bone 3.5, Explora Nova, France).  
 
3.3 Peripheral blood sample collection  
Peripheral blood mononuclear cells (PBMCs) were obtained by venepuncture 
from 10 mL of whole blood from parents, two healthy brothers, subject 3 and 4 
(subject 7 was excluded from the study because on this time he was still a baby) 
and the affected sisters. Blood were diluted 1:1 with Phosphate Saline Buffer 
(PBS) 1X and then stratified in 10 mL of Ficoll solution to allow the separation of 
PBMCs from whole blood. White blood cells ring was collected and washed two 
times whit PBS 1x to eliminate traces of contaminant solutions; PBMCs pellet was 
obtained of 10 minutes centrifugation at 12000 g.  
 
3.4 Sera collection 
Sera samples were collected from all member of the family. Each serum sample 
was obtained from 5 mL of peripheral blood by centrifugation at 400x for 15 
minutes at 4°C and after it was harvested and frozen in aliquots at − 80 °C until 
use.  
 
3.5 Mesenchymal stem cell isolation  
We collect 50 mL of whole blood from the mother, two healthy brothers (subject 
4 and 5) and the affected sisters. MSCs were isolated from 15 mL of heparinized 
blood by two gradient centrifugation (Ficoll GE).   The enriched cell pellet 
(PBMCs) was mixed with 5 ml of additional peripheral blood (from the same 
patient) as red cells are necessary to apply 200μl antibodies cocktail (RosetteSep 
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Mesenchymal Enrichment Cocktail; StemCells); this mix contains bi-specific 
antibody complexes against red blood cells (glycophorin A) and CD3, CD14, 
CD19, CD38 and CD66b positive cells (Stem Cell Technologies Inc). These 
antibody complexes crosslinked the unwanted cells with red blood cells in the 
sample, causing them to pellet together when centrifuged during the second 
Ficoll. The pellet enriched from MSCs was washed in PBS and then cultured in 24 
well plates with Mesencult Basal Medium (StemCell) containing 10% of the 
Stimulatory Supplements for hMSCs (StemCell).54 
 
3.6 Phenotype analysis of MSCs 
We investigated the cell phenotype analysing some mRNA markers. Since positive 
MSCs are expected express CD90 and CD105 transcripts and not to express CD3, 
CD14, CD19, CD45, CD34, we studied the expression of the above cited 
mRNAs.54 This method allows the phenotypic analysis of small numbers of cells 
obtained with stringent stem cell purification techniques.  
 
3.7 DNA and RNA extraction 
We performed DNA extraction from PBMCs or MSCs pellet QIAamp® Blood 
Mini Kit according to datasheet (see supplementary, point A). Part of MSCs dry 
pellet was used to RNA extraction. Procedure was performed using RNeasy Mini 
Kit according to manufactural protocol (see supplementary, point B).  
Quantification of nucleic acids was performed in two steps: in the first step we 
used ThermoScientific™ NanoDrop™ spectrophotometers to evaluate purity and 
concentration, while in second step we used Qubit 4 Fluorometer (Invitrogen) 
also to check the integrity. Nucleics acid will be used for whole exome and 
sequencing and transcriptomic analysis. 
 
3.9 Whole Exome sequencing  
Samples were sent to a facility centre for genomic at University of Verona 
specialized that prepared library fragments of whole exome.  Exome capture was 
performed starting from 500 ng of library as input material with Nextera rapid 
Expanded Exome Capture Kit (Illumina, San Diego, CA, USA), able to target 
exons, UTRs and miRNA DNA fragments. It captures 201,121 exons, the 96.0% 
of CCDS, for a total target region of 62 Mb size (for each sample ware sequenced 
60M of fragments). Whole exome library was sequenced with an Illumina 
NextSeq 500 sequencer (Illumina Inc., San Diego, CA, USA) and 150-bp paired-
end sequences were acquired. 
 
3.10 Methylation sequencing 
Methylation analysis by sequencing was performed by the following steps: 1) 
DNA extraction from and enzymatic fragmentation (450-500 bp), 2) library 
preparation, 3) conversion of unmethylated 5-C into T by bisulphite treatment 
and 4) sequencing. 1) 500 µg of DNA extracted from MSCs were subjected to 
library preparation using the SeqCap® Epi CpGiant Probes (Roche) kit. We 
performed the sequencing using the as reported in the datasheet. For each sample 
has been picked up 500 ng of DNA to perform the enzymatic fragmentation. 2) 
After fragmentation we proceed immediately to adapter ligation and library 
amplification. 3) Only fragments with a size of ~450-500 bp were selected for 
bisulphite conversion step (allow the conversion of unmethylated cytosine in 
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thymine, while methylated one remain cytosine). To evaluate conversion rate, we 
added also a control in 1% concentration. Fagoλ DNA present a unmethylated 
genome and we used his genome as positive conversion control. At this point, 
samples marked with different adapters were polled together for the hybridization 
step. It has been used a probe that allows to interrogate >5.5 million methylation 
sites per sample at single-nucleotide resolution and covered a target region of 80 
Mb. Captured library was amplified using LM-PCR and quantified to evaluate 
concentration, size distribution and quality. 4) Library, prepared as described 
before, was sequenced using an Illumina NextSeq 500sequencer (Illumina Inc., 
San Diego, CA, USA) and 150 bp paired-end sequences were generated.  
 
3.11 Metabolomic profile 
We investigate an untargeted profile, that describes the global profiling of small 
molecules in a biological system without bias. The aim of untargeted 
metabolomics is to determine which of these features is dysregulated between two 
or more samples groups, and in our case between healthy and affected subjects. 
For each subject we used 100 µL of plasma, 200 µL of acetonitrile was added and 
then vortexed for 1 minute. Shake the mixture for 20 minutes, centrifugate at 
10000 rpm for 10 minutes at 4 ° C. Take 150 µL of supernatant and transfer it in a 
glass vial. Plasma metabolites were detected using liquid chromatography 
combined with electrospray ionization tandem mass spectrometry (HPLC–ESI-
MS/MS). Detail above methods are reported by Syslová et al.  2011.55 
The injection volume was 5 μl. Metabolomic profile was measured by HPLC-
Orbitrap in positive and negative polarity. Data was acquired by ThermoSieve v2.2 
software (Thermo Scientific™) and the analyses were performed using XCMS software 
(v. 3.7.1).  
 
3.12 Written informed consent 
Written informed consent was obtained from all subjects of the family.  
 
3.13 Bioinformatic analyses 
3.13.1 Exome sequencing  
The first level of QC was at read level filtering the reads at single base quality 
score, per base sequence content, duplication rate and over-represented 
sequences. Sequenced data (fastq files) were processed with 2 tools: 1) Scythe for 
adapters removal and 2) Sickle for low base quality trimming in 3’ and 5’ 
extremities. Then aligned with the Burrows Wheeler Aligner software BWA 
(version 0.5.7)56 using hg38 human genome assembly as a reference. The family 
members were subject to identity by descent (IBD) estimation and run of 
homozygosity (ROH) test. With these tests we investigated allele frequencies, 
the degree of genetic similarity between individuals, and the presence of long 
chromosomal regions presenting homozygosity within the same individual and 
pair of affected and unaffected individuals.  
Variant sites were called using the GATK Haplotypecaller module, following the 
indications (best practices) of GATK. Single nucleotide variant calls were filtered 
by using the variant quality score recalibration method.57 Each variant was 
annotated reporting, when possible the associated gene, location, predicted 
functional effects, amino acid changes. Multiple pathogenicity prediction 
programs such as SIFT58, Polyphen259, LRP, MutationTaster, FATHMM, 
PROVEAN, MetaSVM, MetaLR, M-cap, CADD prediction scores and gnomAD 
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(exome genomes Minor Allele Frequencies) were used to examine the impact of 
identified variants. All the predictors used are implemented in the Annovar 
software (v. 2018Apr16). 
 
 
3.13.2 Methylation sequencing  
Quality control was performed as described in 3.13.1 section. Bisulphite 
sequencing (BS-Seq) data were aligned with Bismark Bisulphite Mapper (v.0.19.0). 
The pipeline of the analyses can be summarized in three main steps: I) preparation 
of the converted version of reference genome step (all Cs to Ts, and Gs in As), II) 
reads alignment step and III) extraction of methylation level of each cytosine. 
Given the step I, all the alignments in step II used as reference two genomes 
(converted and unconverted). Only reads with best alignment score were kept. 
Multiple reads were discarded. A summary report along with a file containing 
single base methylation information (CG, CHG or CHH contexts) were prepared. 
In order to capture bisulphite converted DNA, probes are designed to hybridize 
both strands of fully methylated, partially methylated and fully unmethylated 
derivatives of the genomic target and then pool them together. The identification 
of differentially methylated regions (DMR) was carried out using DMRfinder 
software pipeline (v 0.3).60 
DMR results were processed by Annovar (2018Apr16) annotation tool 
performing a gene-based annotation to identify SNPs or CNVs, region-based 
annotation to identify variants in specific genomic regions (for example predicted 
transcription factor binding sites, etc.) and a filter-based annotation to identify 
variants that are documented in specific databases such as variant reported in 
dbSNP.  
Differential methylated genes were also submitted to the STRING portal 
(https://string-db.org/) for independent inspection of their predicted 
connections. 
 
3.13.3. Metabolomic profile 
Metabolomic untarget analysis was performed using XCMS software (v. 3.7.1), 
running under the R package (v. 3.5). XCMS identifies features whose relative 
intensity varies between sample groups (i.e. affected and controls) and calculates 
p-values as well as fold changes regarding differences in each of features (that are 
likely to correspond to metabolites in most cases). Dysregulated features were 
reported as plots in a so-called “mirror plot”, reporting intensities of signals 
among groups according to statistical thresholds (p-value ≤ 0.05, fold change ≥ 
1,5 The identification of features was based on METLIN database 
(https://metlin.scripps.edu/). Statistical analysis of metabolite-associated features 









4.1 Previous results of genetic, hystomorfometry and biochemical markers  
As after mentioned, the family have been monitored from 2010, here we reported 
few values of OI clinical markers harvest over the time.  
Since type VI OI is characterized by the absence of PEDF protein, increased 
alkaline phosphatise levels, while the other biochemical parameters of bone and 
mineral metabolism remain unchanged. It has been reported that PEDF is present 
in the plasma of normal individuals at a concentration of approximately 2,76-
28,57μg/ml.61 PEDF serum levels have been assessed in five of six family 




SUBJECT # PEDF conc.  
(2.76-28.57μg/ml µg/mL) 
ALP conc.  
(2-16 µg/L)  
STATUS 
Father (I-1) 9.68 - Healthy 
Mother (I-2) 3.98 - Healthy 
Male Child (II-1) 7.51 - Healthy 
Female Child (II-2) 2.31 21 Affected 
Male Child (II-3) 4.67 - Healthy 
Female Child (II-4) 3.08 68 Affected 
Male Child (II-5) - - Healthy 
Table 2: concentration of PEDF and ALP in the family members (see fig.4) 
PEDF concentration levels within the normal range were found in II-4 affected 
girls, while II-2 showed a lower expression compared to normal range. However, 
considering that in all other type VI patients described so far, included those 
supervised at Verona AOUI PEDF levels were close to 0 µg/mL, PEDF 
concentration of individual II-2 has been considered within the normal range.  
A complete panel of known OI related genes has been previously sequenced by 
dr. Alberto Gandini in all family individuals (table 3, list of investigated genes). 
Gene Chomosome Length of target 
region (bp) 
OI type Inheritance 
LEPRE1 Chr 1 4791 VIII AR 
PLOD2 Chr 3 5079 -*  AR 
COL1A2 Chr 7 8063 I,II,III,IV AD 
BMP1 Chr 8 5263 XII AR 
TMEM38B Chr 9 2382 XIV AR 
LRP5 Chr 11 6301 -* AR 
IFITM5 Chr 11 835 V AR 
SERPINH1 Chr 11 2626 X AR 
LPR6 Chr 12 11256 -* AR 
SP7 Chr 12 3320 XIII AR 
WNT1 Chr 12 2488 XV AR,AD 
PPIB Chr 15 1283 IX AR 
SMPD3 Chr 16 5728 -* AR 
COL1A1 Chr 17 8528 I,II,III,IV AD 
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No mutation showing a segregation of mendelian pattern associated with the 
disease was detected for any gene. 
In 2012 our laboratory performed a hystomorphometric analysis (fig.5) which 
confirmed the presence of the “fish-scale pattern” originally described by F. 
Gloriuex62, a peculiar feature of OI type VI. Fig. 6 show radiographs of subject II-
2 (according to pedigree figure) in which we can appreciate bone thickness al 



















Gene Chomosome Length of target 
region (bp) 
OI type Inheritance 
FKBP10 Chr 17 3393 XI AR 
SERPINF1 Chr 17 1941 VI AR 
LEPREL4 Chr 17 3010 -* AR 
SERPINB5 Chr 18 2990 -* AR 
Figure 6: radiographs of lower limbs and spine of subject II-2 
Table 3: candidates investigated genes. Table reports the list of candidate genes that 
have been sequenced in family members. Genes were sequenced in their CDS and 
UTR regions. * Genes not directly associated to OI spectrum, but related to bone 
diseases such as Bruck syndrome, primary osteoporosis, bone mass decrease, etc.  
A  B 
Figure 5: hystomorphometric analysis of affected children performed by Goldener 
staining. Figure A correspond to subject II-2, while figure B correspond to subject 6.   
Green part in the staining represent mineralized bone, while pink staining represents 
unmineralized osteoid. White arrows in figure B indicates fish scales. 
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4.2 Whole exome sequencing  
Whole exome sequencing (WES) on DNA samples was performed on all the 
family members with the exception of II-5 because too young at time of blood 
collection. Table 4 reports overall mean and median depth value of sequencing of 
the target region for each sample. 
Genetic similarity tested by identity by descend (IBD), was estimate in a sample of 
unrelated Italian individuals showing an average score 0,005 (proportion of IBD, 
pi_IBD). IBD estimation revelled that the similarity between the two parents was 
higher among the population (0,1167). Thus, suggests the parents present some 
degree of consanguinity close to the class of first cousins. In fact, we presumed 
that they could be cousins, considering also their ethnic origin, in which it is al-
lowed marriages between relatives.  
Run of homozygosity (ROH) test, aims to find the presence of long chromosomal 
regions presenting homozygosity in each family member. Consanguineous shared 
long ROH, while outbreed individuals should present short ROH regions. In the 
hypothesis of an autosomal recessive disease, considering that they are consan-
guineous, we identified in affected subjects (II-2, II-4) three ROH chromosomic 
regions: Chr7 position from 8 to 12 millions bp, Chr12 position from 12 to 27 
millions bp and Chr22 position from 24 to 28 million bp. Therefore chr7, chr12 
and chr22 presented a homozygosity region (in the affected and not in the unaf-
fected individuals) whose length was 4 Mb, 15 Mb and 4 Mb respectively (see fig. 
7). 
 
Figure 7: segregation of disease allele (single disease allele) under an AR and 
consanguinity model (ARC model). Figure depicts the family structure and the expected 
genotypes in the case of an AR disease. The parents are supposed to inherited disease 
allele from a common ancestor. Allele 0 refers to wild type allele, while M1 to mutated 
disease allele. The search for pathogenic variants were conducted by studying the 
segregation of disease allele in all the sibship, (full model) or only the affected children 
(Affected based analysis) (only I-1, I-2, II-2 and II-4) indicated by      red arrows. 
As additional quality control check, we evaluated sex chromosomes to assess 
samples identity and avoid errors during library preparation. In table 5 are report-
ed the number of loci on chrX in which each individual present homozygosity (i.e 
0\0 or 1\1\) and heterozygosity. Males, due to their hemizygosity status (one 
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copy of chrX) are expected to show homozygosity to the most of loci (exception 
made for pseudo autosomal region).  
Exome analysis called 22374 high- confidence individual sequence variants. 
When searching for the best pathogenetic candidates we filtered the variants 
according to mapping variant quality (phred_scale > 200) and their depth of 
reading (200 independent reads for the six samples). Then, variants predicted to 
be synonymous or not having a location on either a coding exon, UTR, splice site 
junction or flanking intron and not showing a pattern of AR disease were filtered 
out. Thus, variants have been filtered according to the reported frequency in the 
gnomAD MAF (< 5%), to the prediction deleterious for SIFT and pathogenic 
Polyphen, according to their bioinformatically-estimated severity score of the 
CADD score (>0,85). The analysis did not identify any likely pathogenic variant.  
However, when the same model was tested ignoring the unaffected children (II-1 
and II3) and relating the filtering parameters, 7 variants showed compatible 
segregation. In table 6a,b are reported the variant and their depth reading for each 
individual. It is considerably interesting that SERPINF1 is one of the seven genes 
that come out of the analyses. In the compound heterozygosis model (see fig.8) 
performed on a whole family, a final set of 163 (from 55 genes) candidate variants 
were selected. In thus search, candidates have been filtered in a first step only for 
MAF < 5%, in which we identified 87 variants from 42 genes (genes are listed in 
supplementary at point D). Looking at predictions (SIFT, Polyphen and Cadd 
scores), in addition to the variant frequency we identified 4 candidates genes: 
CERCAM, CHAT, SDHA and WHRN, in table 7a,b. 
 
 
Table 4: depth of coverage per sample, based on intervals of the target region. In the last 
two columns depth in at least 4 and 10 calls for region. Mean= average reading depth, me-
dian= median reading depth, %bases above 4 and above 10= % of bases called more than 
4 or 10 times.  
 
Calls/Individual #1 #2 #3 #4 #5 #6 
Genotype  0\0 178 96 152 108 155 69 
Genotype  0\1 51 213 52 199 61 217 
Genotype 1\1 167 39 187 91 172 81 
Sex XY XX XY XX XY XX 
Table 5: comparison of phenotypic and genetic sex. Loci on chrX showing homozygosity 
and heterozygosity (number of loci presenting the genotype 0\1, over the total number of 
  DEPTH OF READINGS 






66.11 41 90.1 82.3 
I-2 513411304
0 
82.44 51 91.2 85.1 
II-1 449444765
4 
72.17 43 90.2 82.6 
II-2 432932838
7 
69.52 42 89.8 82.0 
II-3 484258764
0 
77.76 49 91.6 85.5 
II-4 507456558
9 
81.49 52 91.8 86.2 
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loci). Heterozygosity was low in individuals I-1, II-1 and II-3, confirming their pheno-
type sex (males). Genotype 0\0: allele wild type, genotype 1\1: alternative allele. 
 
 
Figure 8: segregation of disease allele (two disease alleles M1 and M2) under an AR allele 
heterogeneity model (ARAH model). Figure represents the family structure in which 2 
disease alleles segregates into affected children, one from father (M1) and one for mother 
(M2). Allele 0 indicate the wild type allele, M1|M2 indicate the presence of both mutation 
in the two chromosomes (one from I-1 and one from I-2). The three listed genotypes 
under individuals II-1, II-3 and II-5 represent all the possible expected genotypes.  
Table 6a: variants detected under the AR model analysis, including affected children only.  
This investigation was conducted under the hypothesis that healthy subjects might have 
inherited the disease genotype, but they do not show the disease because a possible low 
penetrance or a very mild phenotype. APOB, HUSB1 and CEP89 showed a compatible 
segregation with AR model but they have been excluded because of the high frequency. 
Table 6b: genotype 0\0 allele wild type, genotype 1\1 alternative allele. Behind the geno-
type is reported depth of reading for each allele. Behind the genotype is reported depth of 








Gene Other info RefSNP Freq 
2 21008652 G A APOB exon26 c.C8216T p.P2739L rs676210 0.292 
6 656143 C A HUS1B exon1 c.G802T p.D268Y rs1211554 0.848 
6 36479198 G C KCTD20 exon3 c.G77C p.S26T rs2239808 0.237 
10 95336798 C T SORBS1 exon28 c.G3362A p.R1121H rs114088633 0.014 
17 1776631 G A SERPINF1 exon7 c.G886A p.E296K rs776811200 0.0002 
17 11640293 A G DNAH9 exon10 c.A1810G p.M604V rs61740059 0.0236 
19 32881908 G A CEP89 exon18 c.C2071T p.R691W rs34626245 0.095 
Gene Gen I-1 Gen I-2 Gen II-1 Gen II-3 Gen II-2 
APOB 0/1 30,14 0/1 22,37 0/0 34,0 0/1 27,28 1/1 0,39 
HUS1B 0/1 27,15 0/1 25,29 0/1 16,25 0/1 17,37 1/1 0,32 
KCTD20 0/1 12,19 0/1 23,11 1/1 0,23 0/1 43,17 1/1 0,36 
SORBS1 0/1 22,14 0/1 28,13 1/1 0,32 0/1 18,16 1/1 0,31 
SERPINF1 0/1 46,20 0/1 48,26 0/1 36,14 1/1 0,39 1/1 0,44 
DNAH9 0/1 130,81 0/1 141,118 1/1 0,201 0/1 145,123 1/1 0,179 








allele Gene Other info RefSNP Frequency 
chr5 236502 G T SDHA exon9:c.G1191T:p.S397S rs200223188 0.0001 
chr5 236534 C T SDHA exon9:c.C1223T:p.S408L rs76896145 0.0207 
chr5 236504 T C SDHA exon9:c.T1193C:p.V398A rs201741295 0.0009889 
chr5 236534 C T SDHA exon9:c.C1223T:p.S408L rs76896145 0.0207 
chr5 236513 C T SDHA exon9:c.C1202T:p.A401V rs201139275 0.000989 
chr5 236534 C T SDHA exon9:c.C1223T:p.S408L rs76896145 0.0207 
chr5 236534 C T SDHA exon9:c.C1223T:p.S408L rs76896145 0.0207 
chr5 236538 C A SDHA exon9:c.C1227A:p.L409L rs75091805 0.0209 
chr9 128423190 G A CERCAM exon3:c.G119A:p.R40K rs556586561 0.0003 
chr9 128434147 G A CERCAM exon10:c.G1015A:p.V339M rs766133803 0.0004954 
chr9 114403926 G T WHRN exon6:c.C1335A:p.N445K rs2274158 0.2476 
chr9 114478722 C T WHRN exon2:c.G668A:p.R223H rs146273185 0.0067 
chr9 114403966 A G WHRN exon6:c.T1295C:p.V432A rs2274159 0.04786 
chr9 114478722 C T WHRN exon2:c.G668A:p.R223H rs146273185 0.0067 
chr9 114424432 C T WHRN exon2:c.G265A:p.A89T rs4978584 0.2530 
chr9 114478722 C T WHRN exon2:c.G668A:p.R223H rs146273185 0.0067 
chr10 49616071 G A CHAT exon2:c.G19A:p.D7N rs1880676 0.2112 
chr10 49622125 C T CHAT exon5:c.C373T:p.L125F rs8178990 0.0467 
chr10 49616573 G A CHAT exon2:c.G4A:p.A2T rs3810950 0.2269 
chr10 49622125 C T CHAT exon5:c.C373T:p.L125F rs8178990 0.0467 
Table 7a: variant detected in compound heterozygosis model analysis. 
 






GenotypeII-2 Genotype II-4 
SDHA 0/0 34,0 0/0 33,0 0/0 35,0 0/0 43,0 0/1 90,16 0/1 119,18 
SDHA 0/0 34,0 0/0 33,0 0/0 35,0 0/0 43,0 0/1 129,20 0/1 155,22 
SDHA 0/0 34,0 0/0 33,0 0/0 35,0 0/0 43,0 0/1 99,16 0/1 127,18 
SDHA 0/0 34,0 0/0 33,0 0/0 35,0 0/0 43,0 0/1 129,20 0/1 155,22 
SDHA 0/0 34,0 0/0 33,0 0/0 35,0 0/0 43,0 0/1 122,20 0/1 147,20 
SDHA 0/0 34,0 0/0 33,0 0/0 35,0 0/0 43,0 0/1 129,20 0/1 155,22 
SDHA 0/0 34,0 0/0 33,0 0/0 35,0 0/0 43,0 0/1 129,20 0/1 155,22 
SDHA 0/0 34,0 0/0 33,0 0/0 35,0 0/0 43,0 0/1 132,20 0/1 160,23 
CERCAM 0/1 76,16 0/0 36,0 0/1 87,11 0/0 47,0 0/1 39,34 0/1 64,26 
CERCAM 0/0 118,0 0/1 189,128 0/0 136,0 0/0 140,0 0/1 183,101 0/1 174,139 
WHRN 0/1 72,45 0/0 36,0 0/1 75,63 0/0 36,0 0/1 69,50 0/1 60,72 
WHRN 0/0 40,0 0/1 35,29 0/0 45,0 0/0 37,0 0/1 34,18 0/1 49,39 
WHRN 0/1 144,86 0/0 36,0 0/1 123,111 0/0 36,0 0/1 132,101 0/1 106,138 
WHRN 0/0 40,0 0/1 35,29 0/0 45,0 0/0 37,0 0/1 34,18 0/1 49,39 
WHRN 0/1 134,136 0/0 46,0 0/1 158,139 0/0 40,0 0/1 156,135 0/1 190,138 
WHRN 0/0 40,0 0/1 35,29 0/0 45,0 0/0 37,0 0/1 34,18 0/1 49,39 
CHAT 0/1 24,13 0/0 51,0 0/0 41,0 0/0 35,0 0/1 26,11 0/1 22,11 
CHAT 0/0 33,0 0/1 61,47 0/1 57,49 0/0 36,0 0/1 61,28 0/1 56,31 
CHAT 0/1 40,34 0/0 36,0 0/0 44,0 0/0 34,0 0/1 33,23 0/1 67,35 
CHAT 0/0 33,0 0/1 61,47 0/1 57,49 0/0 36,0 0/1 61,28 0/1 56,31 
Table 7b: allele 0: allele wild type, allele 1: alternative allele. Behind the genotype is report-




























Cov TR Depth Cov 
I-2 42.3  37.4  88.60 27.5  99.4 % 37.6 
II-2 40.3  35.9  89.10 30.0  99.4 % 51.2 
II-3 40.3  36.8  91.20 21.7  99 % 24.7 
II-4 33.1  29.4  88.80 25.3  99.4 % 39.5 
II-5 40.1  35.5  88.70 27.2  99.4 % 39.1 
4.2 Methylation sequencing 
After alignments (Bismark aligner) we evaluated quality of sequencing and 
mapping efficiency by estimating several parameters as reported in table 8.  
 
Table 8: mapping quality control (Bismark alignment). Total pairs = total number of PE 
fragments that have been sequenced; unique best hit = PE with the single match; map-
ping efficiency = number of PE sequenced mapping properly (i.e. both ends mapped in 
the same region and in the expected DNA strand; leftover = number of alignments re-
mained after quality control filtering; Cov TR = number of PE mapping in the target re-
gion; Depth Cov = average of reading depth in the target region of leftover PE. There are 
the PE used for the following steps to estimate methylation status. 
Subject MetC (Million) UnMetC (Mil-
lion) 
% MetC 
I-2 37.3 195 16.10% 
II-1 40.5 211 16.10% 
II-2 34.1 216 13.60% 
II-3 27.4 153 15.20% 
II-4 30.3 202 13.10% 
Table 9: CpG methylation status. It is reported the number of methylated and unmethylat-
ed Cs (MetC, UnmetC) and the overall methylation status (%MetC) of the genome of each 
individual.  
CpG methylation in the genome often occurs in clusters and CpGs in the same 
region are correlated and perform a similar function. Identification of DRM was 
achieved using DMRfinder tool, that extracts methylation counts and performs a 
modified single-linkage clustering of methylation sites into genomic regions. It 
then compares methylation levels using beta-binomial hierarchical modelling and 
Wald tests. The program determines the valid CpG sites that meet minimum cov-
erage criteria for one or more samples. Then it groups sites that are within a speci-
fied distance of each other into regions. This single-linkage clustering can lead to 
the chaining effect, in which distant CpG sites are placed into the same region due 
an extended series of intermediate sites. After clustering, each region is additional-
ly required to meet a total methylation count minimum (we choose twenty as cut 
of) in each sample before being tested for differential methylation. In the final 
step, DMRfinder tool conducts pairwise tests of sample groups to identify ge-
nomic regions that are differentially methylated. The underlying statistics are 
based on Bayesian beta-binomial hierarchical modelling, which accounts for both 
the biological variation of replicates and the binomial nature of the methylation 
data. Regions that meet the minimum methylation difference (10%) and the max-
imum p- and q-values (q < 0.05) are reported as DMRs.  The analysis highlights 
124 differentially methylated region between affected children and the control 
group, composed by two healthy brothers and the mother. To better understand 
28 
 
the genome localization of DMRs, we annotated the regions and we saw that 55 
of 121 were methylations that occurs into genes (gene names in supplements 
point C), 7 were recognized as promoter, 1 as Transcription factor binding site 
(TF binding site) and 1 as enhancer. We identified also 10 regions that mapped as 
promoter flanking region, 12   as CTCF binding site and 35 open chromatic re-
gions. Transcriptional repressor CTCF also known as 11-zinc finger protein is a 
transcription factor encoded by the CTCF gene. CTCF is involved in many cellu-
lar processes, including transcriptional regulation, insulator activity and regulation 
of chromatin architecture. Methylation status of 124 DMR identified can be di-
vided into 94 that showed a lower methylation in the affected group, while 30 ex-
hibited a higher methylation. In table 10 the schematic summary of DMR types 
and status of methylation.  
DMR type # DMR # of hypo methylated 
in Affected group 
# of hyper methylated in 
Affected group 
Genes 55 - 55 
Open chromatic regions 
(OCR) 
35 28 7 
CTCF binding site 12 8 4 
Promoter flanking region 10 2 8 
Promoter    
TF binding site 7 3 4 
Enhancer 1 1 - 
Promoter flanking region 1 1 - 
Total 121 43 78 
Table 10: annotation of 121 Differentially Methylated Region (q< 0,05) identified. Genes 
show a high methylation, despite OCR that present a lower methylation in the disease 
group. 
Overall, affected group showed a higher methylation profile in comparison with 
healthy subjects. The majority of DMR regions are represented by genes and all of 
the seem to be more methylated in the affected group. In order to discover which 
genes could play a role in the ethiopathogenesis of this strange disease, we anno-
tate our sequences using Annovar tool. We perform a String analysis to asses if 
there was any possible correlation between identified genes based on type of in-
teraction, confidence and molecular action. We exclude 15 entries because they 
were identified as RNA genes. In figure 9a it is showed PPI (protein-protein inter-
action) based on confidence, line thickness indicates the strength of data support, 
colours type of interaction. Exploring the molecular action in the interaction 
showed by STRING, we see the four molecular action clusters (showed in figure 
9b), that see as protagonist 1) RXRA, RAC3 and PSD3; 2) MUC4 and GALTN8; 
3) SHANK2, BRD1, SETD1B, DOT1L and IGHMB2; 4) SNTG2 and SNTA1. 










Figure 9b: Network of interaction focusing on PPI molecular action. Action type are 
explained by different colour lines (as reported in the legend), while the effect types are 
represented by arrow, circles or straight line. Only binding and catalysis action types appears 
in the network. 
Figure 9a: STRING network of physical and functional interactions for DMR genes. 
analysis based on confidence (0.150). Known interaction is showed by cerulean and 
fuchsia lines (from curated database and experimentally determinated); red, green and 
blue lines show the predicted interaction (gene neighbour, gene fusion, gene co-
occurrence); light green, black and light blue display other info as textmining, co-
expression and protein homology. 
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4.3 Metabolomic profile 
To investigate the modulation of metabolomic profile we prefer to analyse only 
the children, excluding the parents, to avoid false positive modulation due to the 
age. Modulated and statistical significative features are plotted in the mirror plot 
(or cloud plot) in fig.10. Green circles represent the upregulated features in affect-
ed children, otherwise red circles represent the downregulates ones. The size of 
each circle corresponds to the (log) fold change of the feature (the average differ-
ence in relative intensity of the peak be-tween sample groups). Larger circles cor-
respond to peaks with greater fold changes. The shade of colour is used to repre-
sent p-value, with brighter circles having lower p-values. The retention time cor-
rected (TIC) total ion chromatograms are also overlaid in gray in the background 
of the figure. Metabolomic profile show a general down regulation of some me-
tabolites in comparison with the healthy group.  
 
Figure 10: cloud plot of the modulated features (fold change ≥1.5, p-value≤ 0.05). Feature 
signals belonging to molecules defined by m/z and retention time. Differential analysis is 
based on the intensity of the signals in affected versus unaffected individuals. Green up 
modulation, red down modulation) between affected and healthy group.  
Cloud plot recognized 647 modulated features, the known metabolites (in 
METLIN database) are represented by the circles whit black borders, in total 445.  
PCA is an unsupervised method aiming to best explain the variance in a data 
without referring to class labels. The data are summarized into much fewer 
variables called scores which are weighted average of the original variables. The 





Figure 11: PCA plot. Individuals are plotted according to their values of PC1 and PC2 from 
PCA that included all the detected features.  PC1 and PC2 count for the 36 and 23% of the 
total variance, respectively.  
Information (m/z, rt and intensity) of all identified metabolites are processed by 
MetaboAnalyst tool (v.3.0) to perform statistical analyses. Data were processed 
using a univariate analyses method such as Fold-change (FC), T-test and Volcano 
plot analysis. The purpose of fold change is to compare absolute value changes 
between two group means; important features selected by fold-change analysis 
with threshold 2.  A T-test is a type of statistical test that is used to compare the 
means of two groups. has been considered as significative only features with a p-
value adjusted ≤ 0.05. Data are reported in table 11. 
m/z Matabolites Name Adjusted p-value  FDR 
266.9896 dopamine 3-sulfate 1.1074e-12 5.4374e-10 
146.9842 2,3-diphospho-D-glycerate 2.7473e-07 6.7447e-05 
129.0204 1,5-anhydro-D-glucitol 1.1254e-05 0.0011052 
179.0575 dopaquinone 1.9603e-05 0.0016042 
225.0632 2-keto-6-aminocaproate 3.1295e-05 0.0021951 
145.0881 N-acetyl-serotonin glucuronide 4.9289e-05 0.0030251 
425.0129 3-hydroxy-L-kynurenine 0.00019605 0.010695 




269.1412 &gamma-L-glutamyl 5-phosphate 0.00029578 0.012103 
272.0751 S-acetyldihydrolipoamide 0.00081008 0.027177 
185.0445 salicyl-6-hydroxy-2-cyclohexene-on-oyl 0.00087264 0.027177 
209.0682 3-hydroxyquinine 0.0008856 0.027177 
325.1676 11-deoxycorticosterone 0.0011099 0.032057 
353.1771 3-&beta-hydroxyandrost-5-en-17-one 3-sulfate 0.0016607 0.045301 
165.0763 dTDP 0.001755 0.045353 
280.1175 8-oxo-GTP 0.0020966 0.049958 
522.9683 triiodothyronine sulfate 0.0021367 0.049958 
Table 11: modulated metabolites between affected and unaffected individuals (t-test < 
0.05). Metabolites have been named according to their known m/z values.  
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Volcano plot (fig. 12) is a type of scatter-plot that is used to quickly identify 
changes in a data set, it plots significance versus fold-change on the y and x axes, 
respectively. Were considered as important (red circles) only metabolites above 
the thresholds (-log10(p-val) 0,05 and FC ≥ 2).  
 
Figure 12: volcano plot of modulated metabolites between affected and unaffected 
individuals. Pink circles represent features above the threshold. Both fold changes and p-
values are log transformed. The further position from the 0 of y axis the more significant 
association. 
In hierarchical cluster analysis, each sample begins as a separate cluster and the al-
gorithm proceeds to combine them until all samples belong to one cluster. Differ-
ences in the metabolomic profile can of each cluster can be visualized though a 
plot called heatmap (fig. 13), that summarized the high and low expression of a 
metabolite by colours.  
 
Figure 13: heatmap of the 25 most significant modulated metabolites between affected and 
unaffected individuals. Metabolites levels define profiles able to group affected and 
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unaffected separately. Blue represent lower abundance respect the average abundance, as red 
present a higher abundance (distance measure using Euclidean distance, and clustering algorithm 
using ward.D). 
Significative metabolites identified by univariate statistical analysis were used to 
explore which pathway were involved. This analysis refers to KEGG database to 
build the network between the query metabolites.  The significative metabolites 
(query) are represented in red, the neighbours coloured in blue represent the me-
tabolites directly connected with the queries.  Statistical analyses of identified 
pathway have been reported in table 12. 
Pathway Pathway size Overlap size p-value 
Phenylalanine, tyrosine and 
tryptophan biosynthesis 
 
27 4 0.001 
Tryptophan metabolism 
 
Pyrimidine metabolism                      













Vitamin B6 metabolism 32 4 0.03      
Table 12: most significative modulated pathways suggested by metabolomic analysis 






















5. DISCUSSION  
Whole Exome sequencing 
Osteogenesis imperfecta is a rare genetic heterogenous and pathology that can 
generate a wide spectrum of different and peculiar phenotypes. Since 2006, NGS 
identified novel disease associated loci.  In the last twelve years, fifteen OI-related 
genes have been discovered, clarifying the extremely wide genetic heterogeneity of 
OI. Despite the great achievements during this years, there are OI types that still 
lack of a genetic explanation. 
Here we described a study performed at multi-omics levels to elucidate potential 
changes that lead or are associated to an unexplained OI type segregating in a 
nuclear Pakistan family. The study has been undertaken because we estimated that 
the exome analysis was powered enough (power > 80%) to identify the locus (i.e. 
variants or restricted chromosomes regions) linked to the disease, under the 
hypothesis of an Autosomal Recessive disease and Consanguinity (ACR) of the 
parents. In this scenario we firstly searched for chromosomal regions presenting 
homozygosity among the affected individuals (single disease allele in double 
dosage in each affected individual is expected) and not in the unaffected children.  
Exome sequencing, performed in the six family subjects (median depth of reading 
was 40x for each sample), confirmed the consanguinity between the parents 
(probably first cousins). Then, we searched for shared regions of homozygosity 
between affected, since they represent the best candidate regions to contain a 
disease variant. Hence, we found 3 long chromosomal regions presenting 
homozygosity (homozygosity mapping) on chr7, chr12 and chr22.  However, we 
cannot exclude that other smaller shared chromosomes regions are present. 
The searches for the pathogenic variant under the ARC hypothesis in the 3 
chromosomal regions did not revealed any strong candidate. These results can 
have different explanations  1) the pathogenic variant maps on a detected 
homozygosity region but is not located inside the protein coding region (thus not 
sequenced in the present study and therefore not detected); 2) the pathogenic 
variant is  in a protein coding region that has been sequenced at a very low (or 
null) depth (we estimated that the 18% of the target region presented a depth of 
reading low than 10 calls per base); 3) the disease genotype present an incomplete 
penetrance (there might be healthy subject harbouring the disease genotype, see 
fig,7) 4) parents harbour two different pathogenic variants that can be detected 
searching for disease allele gene in the hypothesis that affected individuals carry 
two different mutations (one per chromosome, see fig. 8). 
Although it was hard impossible for the present study to explore point 1 (it would 
require a genome sequencing) and point 2 (it would require additional sequencing 
and the usage of a new system to capture exons), but it was possible to investigate 
point 3 and 4. 
When excluding the two unaffected children (affected based analysis, see fig 7, red 
arrows) from the analysis we found some intriguing results. The analysis showed 7 
candidates (reported in table 6), one of them was SERPINF1 gene, the gene of 
Osteogenesis imperfecta type VI. The identified missense variant, E296K, it is 
quite rare (0,024%) and leads an amino acid change in position 296, a glutamic 
acid became a lysine. Prediction analysis suggest that E296K is a high pathogenic 
and damaging mutation.  
To our knowledge, this rare variant has not been reported as disease allele for any 
bone disorder or others. According to its rare frequency in the general population 
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and the possible pathogenetic impact, suggested by bioinformatic predictors, we 
could speculate that this variant might manifest a relative severe effect when in 
combination with other possible and still unknown genetic factor (i.e. other 
relative severe mutation in other OI-related genes risk of disease). The disease will 
appear in subjects presenting both variant (in different genes) that are not 
associated to the disease when present alone. This highly speculative hypothesis 
would imply that the second gene, other than the strong candidate SERPINF1 
map in the region oh homozygosity (chr7, chr12, chr22) in according with the 
high likely ARC model. This will be investigated in the nearest future. 
Compound heterozygosity model (see fig. 8), identified 163 variants from 55 
genes. When applying the filter described in results, point 4.1, 7 genes remained 
(see table 7).  CERCAM gene captured our attention. The analysis showed that 
the parents were carrier for two different mutation (G119A in the mother, 
G1015A in the father).  
It is known that collagen is modified by hydroxylation and glycosylation of 
hydroxylysine residues. This glycosylation is initiated by the β1, O 
galactosyltransferases COLGALT1 and COLGALT2.65 CERCAM protein has 
been described as structurally similar to his paralogs COLGALT1 and 
COLGALT2.65 However, it did not show any galactosyltransferase activity. 
Nevertheless, it is intriguing that CERCAM has been associated to idiopathic 
scoliosis66, suggesting that it may play a role on bone homeostasis.  
Currently we are not able to determine if one of these mutations could be 
associated to the OI-like phenotype, and the results suggest a widely complicated 
scenario, in which were involved two different genes (SERPINF1 and CERCAM). 
Certainly we will perform further investigation to evaluate the SERPINF1 
mutation, evaluating also the penetrance. It is possible that SERPINF1 mutation 
may produce a mild phenotype, explaining that healthy state of individual II-3 
whom presented E296K variant, while the co presence of other variants (such as 
CERCAM), also in different genes may lead to this complex phenotype.  
 
Methylation sequencing 
Epigenetic modulation has been reported to play a crucial role in several disease 
conditions.67 In 2014 it has been described a type V OI associated to methylation, 
in which a de novo C>T transition in the 5′ UTR of the IFITM5 gene was 
reported. This dinucleotide shown to be highly methylated in several tissues and 
particularly in the sperm DNA.68 
Comprehensive analysis of human DNA methylomes revealed distinct DNA 
methylation patterns among different cell types, tissue types and individuals, 
potentially underscoring divergent epigenetic regulation at different scales of 
phenotypic diversity.89  
In our study, methylation profiling (in individuals I-2, II-2, II-3, II-4 and II-5) was 
carried out in MSCs. We choose to study MSCs because are known to be 
multipotent cells and can differentiate into different cells types, including 
osteoblast and chondrocytes, who play a crucial role in Osteogenesis Imperfecta. 
Met-Seq, is a new and challenging analysis, able to evaluate the methylation status 
at single base resolution. Over the entire genome we observed an overall lower 
cytosines methylation in the affected sisters (M-value ~13%), in comparison with 
the unaffected individuals (~16%), as reported in table 8. 
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When studying regions with multiple methylation sites it could be more fruitful to 
investigate the overall methylation at the region level rather than to single sites 
independently. This may be more biologically plausible and would reduce the 
number of statistical tests when searching for differentially methylated regions. 
Therefore, we studied regions of CpG sites rather than the single CpG.  
Differential analysis, identified 121 differential methylated regions (DMRs) in the 
affected individuals, most of them were annotated to map into genes and open 
chromatin regions (OCR), while 31 were mapped as genome regulatory features. 
We saw a higher methylation in gene regions rather than OCR. According with 
the theories which assumed that the transcriptional activity in gene and OCR is 
under DNA methylation control, these foundings suggest that the activity of 
DMRs were different in affected sisters than the unaffected family members.  
It is known that DNA methylation has different functions in different genomic 
contexts. DNA methylation in the protein coding sequence seems to be involved 
in transcription elongation and alternative splicing.69 While, there is evidence that 
methylated CpG islands at transcription start sites (TSS) controls genes 
transcription.70  
In this study we looked at the methylation status as possible marker to distinguish 
affected and unaffected individuals. To explore how methylation affects biological 
process we would need to perform additional studies that focus on gene 
expression and conformational status of chromatin. This would give a broad 
picture on several steps that play a role in the regulation of genes whose products 
might impact on bone homeostasis. The study of methylation performed at high 
resolution (single base) permits to study methylation under many different 
hypotheses. For instance, methylation could be studied at single base level, or as 
average level of target regions (i.e. genes, promoters, transcription factor binding 
sites, enhancers, chromatin regions etc). or investigate if there are nucleotide 
variants that inserts or remove potential methylation target sites. This is still a 
challenging open issue (many statistics tests when methylation is studied at single 
base level) and the still present lack of knowledge on the impact of methylation 
on the different regions of the genome. 
Among the 55 annotated genes, we identified some interesting genes, that showed 
molecular interaction during STRING analysis. Moreover, they are known to be 
involved in bone metabolism, such as RXRA (Retinoid X Receptor Alpha), ELK3 
(ETS Transcription Factor) and GLI2 (GLI Family Zinc Finger 2).  
It is well known that terminal differentiation of multipotent stem cells is achieved 
through a coordinated cascade of activated transcription factors and epigenetic 
modifications that drive gene transcription responsible for unique cell fate.74 In a 
recent study, has been assessed that RUNX2, C/EBP, retinoid X receptor 
(RXRA), and vitamin D receptor (VDR) binding sites, are genes vital for 
osteogenic identity.74 RXRs is known to be  partners for a huge number of other 
nuclear receptors, playing a coordinating role  in several  signalling pathways, but 
also RXRs homodimers has been described. Recently, it has been showed that 
RXRs is involved in osteoclastogenesis and bone remodelling75.  It is able to 
control transcription of bone-forming osteoblasts and bone-resorbing osteoclasts, 
both through heterodimerization with other nuclear receptors and through RXR 
homodimerization.75  
 ETS Transcription Factor, or ELK3, it is known to play a crucial role as negative 
regulator of transcription, but it is able to activate transcription when it is co-
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expressed with RAS, SRC or MOS. Several studies described ELK3, SOX10 and 
SOX18 as critical for neural crest development,76 but, surprisingly, they were 
described also as up-regulated gene in distraction osteogenesis, also if they are not 
involved in postnatal bone repair.77  
In 2010, Kesper et al, reported that GLI2 activity is capable to induce osteoblast 
differentiation, stimulating the expression of Ihh target genes in skeletal tissues.78 
In fact, it is showed that a repressor function of Gli2 is likely dispensable for 
endochondral ossification.  
Considering this foundings, the crucial role of retinoid X receptor in bone 
homeostasis, the activity of GLI2 during ossification and the up regulation of 
ELK3 in distraction osteogenesis, we want to deepen if the methylation status of 
this genes reflects the expression level, (trough transcriptomics data analysis). The 
comparison of methylation and expression data may allow to evaluate the role of 
these genes in the pathology. For these reasons we are performing transcriptomic 
investigation, aimed to compare expression levels to epigenetic data, to truly 
inhabits methylation signals. 
 
Metabolomic analysis 
Metabolomics represent the unique biochemical fingerprint of all cellular 
processes, it allows to deeper into the actual phenotype of any biological system.79 
Here we describe the results obtained by an untarget analysis performed on the 
serum of the family members. Most of the “metabolites signals” that have been 
detected cannot be easily recognize in a known metabolites because the database 
that associates a metabolite to a given signal is still incomplete.  
The metabolomic analysis on children, (in which we investigated only II-1, II-2, 
II-3, II4 and II-5 individuals), identified 5340 signals, 647 of them resulted 
identified as significative modulated (p ≤ 0,05) metabolites between affected and 
unaffected individuals. It is intriguing that the principal component analysis (PCA) 
that included all the detected signals showed affected and unaffected individuals 
in distinct regions of the PC1 and PC2 plot (fig. 11). This analysis presents a 
strong bias due to the low sample size and to the fact that the affected individuals 
are female and unaffected individuals are males and therefore we cannot exclude 
that PCA is distinguishing gender effects from disease effects.  In general, we 
observed a lower expression of most of identified metabolites in affected than in 
unaffected individuals.  
Enrichment analysis revealed the following 4 significant “phenylalanine, tyrosine 
and tryptophan biosynthesis”, “tryptophan metabolism, pyrimidine metabolism”, 
and “Vitamin B6 metabolism”.  
Tryptophan metabolism (see table 12) and serotonin N-acetyl glucuronide (in tab. 
11) could be associated with some signalling molecules in the nervous system, 
including neuropeptides and neurotransmitters that have been identified in 
bone.80,81 Recently, it has been suggested that peripheral serotonin produced in the 
gut was a major negative regulator of osteoblast proliferation.82 In fact, osteoclasts 
are able to synthetize serotonin that acts locally to induce osteoclast precursors 
differentiation.83 The current hypothesis about serotonin role in bone asserts that 
a low amount of serotonin in bone microenvironment would trigger the 
proliferation of both osteoclast and osteoblast precursors.83 It is noteworthy that 
serotonin biosynthesis starts from tryptophan and 5-HTP (5-hydroxy-
tryptophan), and it needs Vitamin B6.84  
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Another modulated pathway, found in our analysis was the phenylalanine, tyrosine 
and tryptophan biosynthesis. It has been demonstrated that 3,4-dihydroxy-L-
phenylalanine, also known as DOPA,  enhances the osteogenic differentiation in 
vitro of human bone marrow-derived mesenchymal stem cells (h BM-MSCs).85 
Moreover many studies showed that damaged or missing sympathetic nerves leads 
to the abnormal bone formation and bone mass86 suggesting that osteoblasts may 
respond to neurotransmitters such as dopamine.83 Dopamine biosynthesis  starts 
from tyrosine amino acid, that in turn derived from the conversion of 
phenylalanine to tyrosine (table 12).  Some studies reported that dopamine 
receptors are expressed in osteoblast and were functional to promote bone 
mineralization.  
All these reports together with our results would suggest that tryptophan, 
phenylalanine, tyrosine and L-dopa alteration may reflect an impaired proliferation 
and mineralization of bone cells, affecting and being markers of bone remodelling 
process. Moreover, it should be noted that Vitamin B6 it always necessary to 




The here reported study describes the results from exome, methylome and 
metabolome studies performed on a family in which is likely to segregate a form 
of type VI OI. The exome analysis was not able to identify a clear pathogenic 
variant. However, several chromosomes regions and possible candidate genes 
have been suggested when testing different segregation models. The intriguing 
results is that among the associated variants, many of them belong to gene 
associated to bone homeostasis raising the still highly speculative hypothesis that 
more than one gene might be concurrently associated to the affected status within 
the family. Methylation analysis showed an overall different methylation level 
between affected and unaffected as well as several chromosomal regions linked to 
RXRA, ELK3 and GLI2 bone homeostasis genes. These regions may serve as 
markers for the disease status and might help in shedding light on the possible 
pathogenic steps associated to the disease. Metabolome studies offered similar 
results, adding further information of the defective mechanism involved in the 
disease.  
The future investigation will try to enhance and integrate the results from the 
present omics (transcriptomic analysis is ongoing) into a context of system 
biology aimed to depict and clarify the defects and biological processes associated 














7. SUPPLEMENTARY MATERIALS 
A. DNA EXTRACTION PROTOCOL 
QIAamp® Blood Mini Kit  
The QIAamp Blood Mini Kit (cat. nos. 51104 and 51106) can be stored at room temperature (15–
25°C) for up to 12 months. Reconstituted QIAGEN Protease is stable for 2 months when stored at 
2–8°C.  
 Further information  
 QIAamp DNA Mini and Blood Mini Handbook  www.qiagen.com/HB-0329  
 Safety Data Sheets  www.qiagen.com/safety  
 Technical assistance  support.qiagen.com  
 
Notes before starting  
 Perform all centrifugation steps at room temperature (15–25°C).  
 Dissolve any precipitates in Buffer AL by warming at 56°C until the precipitate has dis-
solved.  
 Add ethanol to Buffer AW1 and Buffer AW2 concentrates, as indicated on the bottle.  
 Add Protease Solvent to lyophilized QIAGEN Protease, as indicated on the label.  
 Equilibrate samples to room temperature (15–25°C).  
 Preheat a water bath or heating block to 56°C.  
 
1. Pipet 20 μl QIAGEN Protease into a 1.5 ml microcentrifuge tube. Add 200 μl sample.  
 
If the sample volume is less than 200 μl, add the appropriate volume of PBS.  
2. Add 200 μl Buffer AL. Mix thoroughly by vortexing.  
3. Incubate at 56°C for 10 min. Briefly centrifuge the 1.5 ml microcentrifuge tube to remove drops 
from the lid.  
4. Add 200 μl ethanol (96–100%). Mix thoroughly by vortexing. Briefly centrifuge the tube 
to remove drops from the lid.  
5. Pipet the mixture onto the QIAamp Mini spin column (in a 2 ml collection tube) and 
centrifuge at 6000 x g (8000 rpm) for 1 min. Discard the flow-through and collection tube.  
 
Note  When preparing DNA from buffy coat or lymphocytes, centrifugation at full speed 
is recommended to avoid clogging.  
6. Place the QIAamp Mini spin column in a new 2 ml collection tube and add 500 μl Buff-
er AW1. Centrifuge at 6000 x g (8000 rpm) for 1 min. Discard the flow-through and collec-
tion tube.  
7. Place the QIAamp Mini spin column in a new 2 ml collection tube and add 500 μl Buff-
er AW2. Centrifuge at full speed (20,000 x g; 14,000 rpm) for 3 min. Discard the flow-
through and collection tube.  
8. Recommended  Place the QIAamp Mini spin column in a new 2 ml collection tube 
(not provided) and centrifuge at full speed for 1 min. This eliminates the chance of possible 
Buffer AW2 carryover.  
9. Place the QIAamp Mini spin column in a new 1.5 ml microcentrifuge tube (not provid-
ed), add 200 μl Buffer AE or distilled water and incubate at room temperature (15–25°C) 






B. RNA EXTRACTION 
RNeasy® Mini Kit, 
Notes before starting  
If purifying RNA from cell lines rich in RNases, or tissue, add either 10 μl β-mercaptoethanol (β-
ME), or 20 μl 2 M dithiothreitol (DTT),* to 1 ml Buffer RLT. Buffer RLT with β-ME or DTT can 
be stored at room temperature for up to 1 month.  
 Add 4 volumes of ethanol (96–100%) to Buffer RPE for a working solution.  
 Remove RNAlater® stabilized tissue from the reagent using forceps.  
 For RNeasy Protect Mini Kit (cat. nos. 74124 and 74126), please start with the Quick-Start 
Protocol RNAlater RNA Stabilization Reagent, RNAlater TissueProtect Tubes, and RNeasy Protect Kits.  
 
* This option not included for cells in handbook; handbook to be updated.  
1. Cells  Harvest a maximum of 1 x 107 cells, as a cell pellet or by direct lysis in the vessel. Add 
the appropriate volume of Buffer RLT (see Table 1).  
Tissues  Do not use more than 30 mg tissue. Disrupt the tissue and homogenize the lysate in the 
appropriate volume of Buffer RLT (see Table 1). Centrifuge the lysate for 3 min at maximum 
speed. Carefully remove the supernatant by pipetting, and use it in step 2.  
2. Add 1 volume of 70% ethanol to the lysate, and mix well by pipetting. Do not centrifuge. Pro-
ceed immediately to step 3.  
Transfer up to 700 μl of the sample, including any precipitate, to an RNeasy Mini spin column 
placed in a 2 ml collection tube (supplied). Close the lid, and centrifuge for 15 s at ≥8000 x g. Dis-
card the flow-through.  
 
Optional  For DNase digestion, follow steps 1–4 of “On column DNase digestion” in Quick-Start 
Protocol RNeasy Mini Kit, Part 2.  
4. Add 700 μl Buffer RW1 to the RNeasy spin column. Close the lid, and centrifuge for 15 s at 
≥8000 x g. Discard the flow-through.  
5. Add 500 μl Buffer RPE to the RNeasy spin column. Close the lid, and centrifuge for 15 s at 
≥8000 x g. Discard the flow-through.  
6. Add 500 μl Buffer RPE to the RNeasy spin column. Close the lid, and centrifuge for 2 min at 
≥8000 x g.  
 
Optional  Place the RNeasy spin column in a new 2 ml collection tube (supplied). Centrifuge at 
full speed for 1 min to dry the membrane.  
7. Place the RNeasy spin column in a new 1.5 ml collection tube (supplied). Add 30–50 μl RNase-
free water directly to the spin column membrane. Close the lid, and centrifuge for 1 min at ≥8000 
x g to elute the RNA.  
8. If the expected RNA yield is >30 μg, repeat step 7 using another 30–50 μl of RNase-free water, 
or using the eluate from step 7 (if high RNA concentration is required). Reuse the collection tube 
from step 7.  
 




























































D. CANDIDATES GENE INDENTIFIED IN THE COMPOUND HET-
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